Ask AI
ProCE Banner Series

Targeted Therapeutics in CLL and MCL: Applying Emerging BTK Inhibitor Therapy Data to Practice

Join us for this dynamic, case-based, CME-certified live webinar, in which an expert panel will discuss recent data and key areas of consensus and controversy involving BTK inhibitor therapies in CLL/SLL and MCL. Sign up today!

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

  AMA
Who Should Attend

This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL.

All Events

Targeted Therapeutics in CLL and MCL: Applying Emerging BTK Inhibitor Therapy Data to Practice

Past Events

January

09

2024

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

Welcome and Program Overview 

Overview of BTK inhibitors 

Clinical Application of Recent BTK Inhibitor Therapy Data for CLL/SLL

Clinical Application of Recent BTK Inhibitor Therapy Data for MCL

Addressing Challenges With Adherence to BTK Inhibitor Therapy

Discussion on the Future of BTK Inhibitor Therapy 

Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with CLL/SLL and MCL. 

Target Audience
This global educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate differences between covalent and noncovalent BTKi in terms of molecular characteristics, selectivity, clinical data, approved indications, dosing, safety profiles, and efficacy and their respective impact on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with CLL/SLL or MCL, taking into consideration global indications, regional/national expert recommendations, and recent practice-changing clinical trial results
  • Select an optimal sequence of targeted therapies for patients with resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
  •  Identify patients who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Lilly.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191